Hyperhomocysteinemia in hemodialysis patients: Effects of 12-month supplementation with hydrosoluble vitamins

Kidney International

Volumn 58, Issue 2, 2000, Pages 851-858

  Tremblay, R ^a   Bonnardeaux, A ^a   Geadah, D ^a   Busque, L ^a   Lebrun, M ^a   Ouimet, D ^a   Leblanc, M ^a  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

Atherosclerotic cardiovascular disease; End stage renal disease; Folate; Homocysteine; Pyridoxal 5' phosphate; Vitamin B12

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; DIA VITE; FOLIC ACID; HOMOCYSTEINE; HYDROSOLUBLE VITAMIN; MULTIVITAMIN; PYRIDOXAL 5 PHOSPHATE; PYRIDOXINE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLIC ACID BLOOD LEVEL; GENOTYPE; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 0033860208     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2000.00234.x     Document Type: Article

References (50)

1. Hyperhomocysteinemia and low pyridoxal phosphate: Common and independent reversible risk factor for coronary artery disease
2. Total plasma homocysteine and cardiovascular risk profile: The Hordaland homocysteine study
3. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease
4. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intake
5. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians
6. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study
7. Hyperhomocysteinemia is associated with atherosclerotic occlusive arterial accidents in predialysis chronic renal failure patients
8. Excess prevalence of fasting and postmethionine loading hyperhomocysteinemia in stable renal transplant recipients
9. Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients
10. Folic acid, pyridoxine, cobalamin and homocysteine and their relationship to cardiovascular disease in end-stage renal disease
11. Hyperhomocysteinemia and the risk of vascular disease in hemodialysis patients
12. Hyperhomocysteinemia as a possible role for atherosclerosis in CAPD patients
13. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
14. Plasma homocysteine in renal failure
15. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study
16. Folic acid, an innocuous means to reduce plasma homocysteine
17. Impaired homocysteine metabolism in early-onset cerebral and peripheral arterial occlusive disease
18. Disordered methionine/homocysteine metabolism in premature vascular disease: Its occurrence, cofactor therapy, and enzymology
19. Treatment of mild hyperhomocysteinemia in vascular disease patients
20. Vitamin requirements for the treatment of hyperhomocysteinemia in humans
21. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients
22. Plasma homocysteine in acute myocardial infarction: Homocysteine lowering effect of folic acid
23. Natural history of cystathionine beta synthase deficiency
24. The natural history of vascular disease in homocystinuria and the effects of treatment
25. Appropriate vitamin therapy for dialysis patients
26. Water soluble vitamins in chronic hemodialysis patients and need for supplementation
27. Vitamin B6 and hemodialysis: The impact of high-flux/high-efficiency dialysis and review of the literature
28. Low serum vitamin B12 levels in chronic high-flux haemodialysis patients
29. Erythrocyte vitamin B1, B2 and B6 and erythropoietin
30. 12 levels after erythrocyte treatment
31. Brief report: Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of plasma homocysteine in hemodialysis patients
32. Metabolic consequences of folate-induced reduction of hyperhomocysteinemia in uremia
33. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients
34. 12, and folic acid in end-stage renal disease during low-dose supplementation with folic acid
35. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: Possible implication for prevention of vascular disease
36. The effect of high dose pyridoxine and folic acid supplementation on serum lipid and plasma homocysteine concentration in dialysis patients
37. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine levels in chronic renal failure
38. Folic acid treatment of hyperhomocysteinemia in dialysis patients
39. No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinemia in haemodialysis patients
40. Short term betaine therapy fails to lower fasting total plasma homocysteine levels in hemodialysis patients maintained on chronic folic acid supplementation
41. Effect of folic acid and betaine on fasting and postmethionine loading plasma homocysteine and methionine levels in chronic haemodialysis patients
42. Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid
43. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations
44. Hyperhomocysteinemia induced by folic acid deficiency and methionine load: Applications of a modified HPLC method
45. A candidate genetic risk factor for vascular disease: A common mutation in methylene tetrahydrofolate reductase
46. Vitamin levels in chronic renal failure and need for supplementation
47. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations
48. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients
49. Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis
50. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease